Connect with us

Health

Guardion Health Sciences Completes Delivery of $875,000 Order to Malaysian Corporate Customer Nasdaq:GHSI

Published

on

Fulfills Initial Order of Astramern from Astramune Sdn Bhd, a Subsidiary of Ho Wah Genting Berhad

San Diego, California, June 30, 2020 (GLOBE NEWSWIRE) — Guardion Health Sciences, Inc. (“Guardion” or the “Company”) (Nasdaq: GHSI) announced today that it has completed shipment of Astramern to Astramune Sdn Bhd, a subsidiary of Ho Wah Genting Berhad (“HWGB”) (KLSE:9601), a Malaysian company listed on the Malaysian Stock Exchange (Industrial Products sector). As such, the Company will recognize this shipment in operating revenues during the three months ending June 30, 2020. This order was previously announced by the Company on April 1, 2020.

Astramern is a sister product to acuMMUNE, the Company’s proprietary immuno-supportive complex and the flagship product of the Company’s recently-acquired NutriGuard business line. acuMMUNE and Astramem are novel nutraceutical formulations designed to support the body’s immune function – including enhancing interferon-mediated anti-viral mechanisms and reducing the inflammation associated with certain respiratory infections. Additional information on acuMMUNE can be obtained at https://www.nutriguard.com/acummune/.

Dr. David Evans, Ph.D., Guardion’s interim President and Chief Executive Officer, commented, “We are pleased to announce the successful fulfillment of our first significant corporate order for our immune support product line. We believe that this demonstrates our ability to design, manufacture and deliver large-scale orders that originate from our NutriGuard brand, which was accomplished in spite of the operational and logistical challenges faced by traditional manufacturers in this current challenging business environment. Our team is continuing to evaluate other similar business opportunities in the Far East and elsewhere.”

Dr. Evans concluded. “I want to thank our entire team, and particularly Dr. Mark McCarty, the original founder of NutriGuard, and now a senior scientist/consultant to Guardion, who led the development of this proprietary formulation.”

About Guardion Health Sciences, Inc.

Guardion is a specialty health sciences company (i) that develops medical foods and medical devices in the ocular health marketplace and (ii) that is developing nutraceuticals that the Company believes will provide medicinal and health benefits to consumers. Information and risk factors with respect to Guardion and its business, including its ability to successfully develop and commercialize its proprietary products and technologies, may be obtained in the Company’s filings with the SEC at www.sec.gov.

About NutriGuard

NutriGuard formulates high-quality nutraceuticals, which are designed to supplement consumers’ diets. NutriGuard uses industry standards to establish the safety and efficacy of the products it develops and markets, maintains that commitment through prudent manufacturing and quality assurance programs, and only uses manufacturers who comply with FDA current Good Manufacturing Practices (cGMP) requirements. Guardion plans to increase NutriGuard’s existing customer base and build on its product platform by making NutriGuard products available to patients directly and through recommendations by their physicians.

About VectorVision®

VectorVision® specializes in the standardization of contrast sensitivity, glare sensitivity, low contrast acuity, and ETDRS acuity vision testing. Its patented standardization system provides the practitioner or researcher the ability to delineate very small changes in visual capability, either as compared to the population or from visit to visit. VectorVision’s® patented technology is considered the standard of care for clinical trials. VectorVision® is a wholly owned subsidiary of Guardion.

Forward-Looking Statement Disclaimer

With the exception of the historical information contained in this news release, the matters described herein may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements preceded by, followed by or that otherwise include the words “believes,” “expects,” “anticipates,” “intends,” “projects,” “estimates,” “plans” and similar expressions or future or conditional verbs such as “will,” “should,” “would,” “may” and “could” are generally forward- looking in nature and not historical facts, although not all forward-looking statements include the foregoing. These statements involve unknown risks and uncertainties that may individually or materially impact the matters discussed herein for a variety of reasons that are outside the control of the Company, including, but not limited to, the Company’s ability to raise sufficient financing to implement its business plan, the impact of the COVID-19 pandemic on the Company’s business, operations and the economy in general, and the Company’s ability to successfully develop and commercialize its proprietary products and technologies. Readers are cautioned not to place undue reliance on these forward- looking statements, as actual results could differ materially from those described in the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company’s filings with the SEC, which are available at the SEC’s website (www.sec.gov). The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Relations Contact: Porter, LeVay & Rose, Inc.

Michael Porter
Telephone:(212) 564-4700
E-mail:mike@plrinvest.com

Continue Reading
Advertisement
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Health

Coronavirus live updates: Experts call for states to shut down again as deaths trend upward

Published

on

By

Continue Reading

Health

Coronavirus live updates: As coronavirus hospitalizations climb, Trump sidelines health advisors

Published

on

By

Continue Reading

Health

Public Health Announces 69 Additional Positive COVID-19 Cases in Delaware, 2 New Deaths

Published

on

By

Public Health Announces 69 Additional Positive COVID-19 Cases in Delaware, 2 New Deaths – State of Delaware News



Read the latest news on coronavirus in Delaware. More Info





SMYRNA (July 8, 2020) – The Delaware Division of Public Health (DPH) is announcing 69 additional positive cases of coronavirus disease 2019 (COVID-19) in Delaware, as of 6:00 p.m., Wednesday, July 8, 2020. Two new deaths were also reported. In addition, 63 individuals are currently hospitalized due to COVID-19 in Delaware, 12 of whom are critically ill.

A total of 517 Delawareans have passed away due to complications from COVID-19. Individuals who have died from COVID-19 ranged in age from 21 to 104 years old. Of those who have died, 273 were females and 244 were males. A total of 249 individuals were from New Castle County, 92 were from Kent County, and 176 were from Sussex County.

The most recent deaths announced today ranged in age from 74 to 94. One individual was female and one was male. One individual was a resident of New Castle County and one was a resident of Sussex County. One individual had underlying health conditions.

To protect personal health information, DPH will not confirm specific information about any individual case, even if other persons or entities disclose it independently.

The latest Delaware COVID-19 case statistics* cumulatively since March 11, provided as of 6 p.m., Wednesday, July 8, include:

  • 12,531 total positive cases
  • New Castle County cases: 5,626
  • Kent County cases: 1,795
  • Sussex County cases: 5,008
  • Unknown County: 102
  • Females: 6,899; Males: 5,614; Unknown: 18
  • Age range: 0 to 104
  • Currently hospitalized: 63; Critically ill:12 (This data represents individuals currently hospitalized in a Delaware hospital regardless of residence, and is not cumulative.)
  • Delawareans recovered: 6,901
  • 117,674 negative cases**
    *Data are provisional and subject to change.
    **Data on negative cases are preliminary, based on negative results reported to DPH by state and commercial laboratories performing analysis.

Delaware is considering patients fully recovered seven days after the resolution of their symptoms. Three days after symptoms resolve, patients are no longer required to self-isolate at home; however, they must continue to practice strict social distancing for the remaining four days before returning to their normal daily routine.

Additional demographic data on COVID-19 cases and deaths, including race/ethnicity, more age-specific data and rates information by ZIP code, can be found on the Division of Public Health’s My Healthy Community data portal.

Information about testing events, including community testing sites and free-standing sites operated by the health care systems and hospitals, will be listed on the testing section of the Delaware coronavirus website at: https://coronavirus.delaware.gov/testing/. Please note for saliva-based testing events that while long-term care facilities are listed on the Curative registration site, they are not community-based testing sites. The long-term care facility registrations are not open to the public nor to family members of long-term care residents.

If you are sick with any of the following symptoms, stay home: fever, cough, shortness of breath, sore throat, muscle aches, fatigue, chills, shaking with chills, loss of smell or taste. Other symptoms such as headache or digestive symptoms (vomiting, diarrhea, abdominal pain or lack of appetite) have been identified as potential symptoms related to COVID-19 and may prompt further screening, action or investigation. If you are sick and need essential supplies, ask someone else to go to the grocery store or the pharmacy to get what you need.

If you believe you have been exposed to someone with COVID-19, or have symptoms of illness, make sure to distance yourself from others, particularly vulnerable populations. Older adults and people of any age with serious underlying medical conditions – including serious heart conditions, chronic lung conditions, including moderate to severe asthma, severe obesity and those who are immunocompromised, including through cancer treatment – may have a higher risk for severe illness from COVID-19.

Individuals who have complaints about individuals violating public gathering restrictions should contact state or local law enforcement. Concerns that a business may be violating operating restrictions should be directed to: HSPContact@delaware.gov. Questions related to business re-openings or operations as businesses reopen should go to COVID19FAQ@delaware.gov.

Individuals with questions about COVID-19 should call Delaware 2-1-1, individuals who are deaf or hard of hearing can text their ZIP code to 898-211, or email info@delaware211.org. Hours of operation are 8:00 a.m. to 9:00 p.m. Monday through Friday; 9:00 a.m. to 5:00 p.m. Saturday and Sunday. Medically related questions regarding testing, symptoms, and health-related guidance can be submitted by email at DPHCall@delaware.gov. Questions regarding unemployment claims should be emailed to: UIClaims@delaware.gov.

In addition, the Division of Public Health asks any Delaware health care, long-term care, residential, or other high-risk facility with questions or concerns to email: DPH_PAC@delaware.govor call the DPH Call Center at 1-866-408-1899 and press ext. 2.

DPH will continue to update the public as more information becomes available. For the latest on Delaware’s response, go to de.gov/coronavirus.

image_printPrint

Related Topics:  

Graphic that represents delaware news on a mobile phone

Keep up to date by receiving a daily digest email, around noon, of current news release posts from state agencies on news.delaware.gov.

Here you can subscribe to future news updates.

SMYRNA (July 8, 2020) – The Delaware Division of Public Health (DPH) is announcing 69 additional positive cases of coronavirus disease 2019 (COVID-19) in Delaware, as of 6:00 p.m., Wednesday, July 8, 2020. Two new deaths were also reported. In addition, 63 individuals are currently hospitalized due to COVID-19 in Delaware, 12 of whom are critically ill.

A total of 517 Delawareans have passed away due to complications from COVID-19. Individuals who have died from COVID-19 ranged in age from 21 to 104 years old. Of those who have died, 273 were females and 244 were males. A total of 249 individuals were from New Castle County, 92 were from Kent County, and 176 were from Sussex County.

The most recent deaths announced today ranged in age from 74 to 94. One individual was female and one was male. One individual was a resident of New Castle County and one was a resident of Sussex County. One individual had underlying health conditions.

To protect personal health information, DPH will not confirm specific information about any individual case, even if other persons or entities disclose it independently.

The latest Delaware COVID-19 case statistics* cumulatively since March 11, provided as of 6 p.m., Wednesday, July 8, include:

  • 12,531 total positive cases
  • New Castle County cases: 5,626
  • Kent County cases: 1,795
  • Sussex County cases: 5,008
  • Unknown County: 102
  • Females: 6,899; Males: 5,614; Unknown: 18
  • Age range: 0 to 104
  • Currently hospitalized: 63; Critically ill:12 (This data represents individuals currently hospitalized in a Delaware hospital regardless of residence, and is not cumulative.)
  • Delawareans recovered: 6,901
  • 117,674 negative cases**
    *Data are provisional and subject to change.
    **Data on negative cases are preliminary, based on negative results reported to DPH by state and commercial laboratories performing analysis.

Delaware is considering patients fully recovered seven days after the resolution of their symptoms. Three days after symptoms resolve, patients are no longer required to self-isolate at home; however, they must continue to practice strict social distancing for the remaining four days before returning to their normal daily routine.

Additional demographic data on COVID-19 cases and deaths, including race/ethnicity, more age-specific data and rates information by ZIP code, can be found on the Division of Public Health’s My Healthy Community data portal.

Information about testing events, including community testing sites and free-standing sites operated by the health care systems and hospitals, will be listed on the testing section of the Delaware coronavirus website at: https://coronavirus.delaware.gov/testing/. Please note for saliva-based testing events that while long-term care facilities are listed on the Curative registration site, they are not community-based testing sites. The long-term care facility registrations are not open to the public nor to family members of long-term care residents.

If you are sick with any of the following symptoms, stay home: fever, cough, shortness of breath, sore throat, muscle aches, fatigue, chills, shaking with chills, loss of smell or taste. Other symptoms such as headache or digestive symptoms (vomiting, diarrhea, abdominal pain or lack of appetite) have been identified as potential symptoms related to COVID-19 and may prompt further screening, action or investigation. If you are sick and need essential supplies, ask someone else to go to the grocery store or the pharmacy to get what you need.

If you believe you have been exposed to someone with COVID-19, or have symptoms of illness, make sure to distance yourself from others, particularly vulnerable populations. Older adults and people of any age with serious underlying medical conditions – including serious heart conditions, chronic lung conditions, including moderate to severe asthma, severe obesity and those who are immunocompromised, including through cancer treatment – may have a higher risk for severe illness from COVID-19.

Individuals who have complaints about individuals violating public gathering restrictions should contact state or local law enforcement. Concerns that a business may be violating operating restrictions should be directed to: HSPContact@delaware.gov. Questions related to business re-openings or operations as businesses reopen should go to COVID19FAQ@delaware.gov.

Individuals with questions about COVID-19 should call Delaware 2-1-1, individuals who are deaf or hard of hearing can text their ZIP code to 898-211, or email info@delaware211.org. Hours of operation are 8:00 a.m. to 9:00 p.m. Monday through Friday; 9:00 a.m. to 5:00 p.m. Saturday and Sunday. Medically related questions regarding testing, symptoms, and health-related guidance can be submitted by email at DPHCall@delaware.gov. Questions regarding unemployment claims should be emailed to: UIClaims@delaware.gov.

In addition, the Division of Public Health asks any Delaware health care, long-term care, residential, or other high-risk facility with questions or concerns to email: DPH_PAC@delaware.govor call the DPH Call Center at 1-866-408-1899 and press ext. 2.

DPH will continue to update the public as more information becomes available. For the latest on Delaware’s response, go to de.gov/coronavirus.

image_printPrint

Related Topics:  

Graphic that represents delaware news on a mobile phone

Keep up to date by receiving a daily digest email, around noon, of current news release posts from state agencies on news.delaware.gov.

Here you can subscribe to future news updates.





Continue Reading

Trending